Urinary albumin excretion in patients with systemic lupus erythematosus without renal disease

Enrique Batlle-Gualda, Ana Carro Martinez, Rocio Alfayate Guerra, Eliseo Pascual

Abstract

**Objectives**—To investigate the prevalence of microalbuminuria, urinary albumin excretion (UAE) between 20–200 µg/min, in systemic lupus erythematosus (SLE) patients without clinical renal disease, and to discover if this could predict the development of renal disease.

**Methods**—This study made six monthly measurements of UAE, creatinine clearance, serological and clinical data in 22 ambulatory women patients with SLE, without clinical renal disease, hypertension, diabetes or heart failure. The patients were followed up for a period of 18 months (four measurements). Age and sex matched healthy controls were used as a comparative group. UAE was measured by nephelometry in three timed overnight urine samples at each visit.

**Results**—There were no significant differences in the creatinine clearance between the control group and the SLE patients. Creatinine clearance did not show significant changes throughout the study period. SLE patients had wide variations in the UAE rate compared with healthy controls. In five patients (5 of 22; 23%), on occasions, there was mild, transient increase in UAE reaching the level of microalbuminuria. During follow up, one patient with basal (4.67 µg/min) and six month (4.73 µg/min) normal UAE rate, was admitted with a nephrotic syndrome confirmed on biopsy examination to be proliferative lupus nephritis. Six months after beginning treatment with prednisone and cyclophosphamide her UAE rate returned to normal values (4.65 µg/min).

**Conclusion**—SLE patients without clinical renal disease may have microalbuminuria, although this does not seem to warrant any specific action.

(UAnn Rheum Dis 1997;56:386–389)

Urinary albumin excretion (UAE) is a more sensitive indicator than urinary total protein for the early detection of renal involvement in some chronic diseases such as diabetes mellitus and hypertension.1 Microalbuminuria has been defined as a UAE of 20–200 µg/min (30–300 mg/24 h), which is undetectable by routine laboratory test such as dipsticks (Albustix).2 At an excretion rate of about 200 µg/min (150–200 mg/l) conventional semiquantitative strips give a positive result for albuminuria. It has been shown that microalbuminuria is a prognostic factor of clinical nephropathy in diabetes mellitus,3 and has been associated with essential hypertension,4 and increased cardiovascular morbidity and mortality in diabetic and non-diabetic patients.5,6 Although poorly understood, endothelial dysfunction has been implicated in the pathogenic mechanism, and microalbuminuria may be a marker of susceptibility to increased permeability of the vascular wall.7

On the other hand, microalbuminuria has also been reported in some rheumatic diseases such as rheumatoid arthritis8—9 and systemic sclerosis,10 and has been associated with limited joint mobility in type I diabetes mellitus,11 but until now few data exist about systemic lupus erythematosus (SLE).12–15 Several cross sectional studies made in SLE patients without clinical renal disease have shown that the UAE is frequently increased,12–15 and mesangial nephropathy has been considered responsible for this,16 although other authors did not find these abnormalities.15 Whether this raised UAE may predict the development of severe renal disease in lupus patients is unknown. With the aim of better defining this issue, we have prospectively measured the UAE, every six months, in 22 SLE patients without clinical renal disease during a period of 18 months (four measurements), and compared their results with an age and sex matched healthy population as a control group.

**Methods**

**PATIENTS**

All the patients diagnosed as having SLE followed up in an outpatient clinic of rheumatology, and with at least four of the American Rheumatism Association (ARA) 1982 revised criteria for the classification of SLE19 were included in this study, if they fulfilled the following criteria: blood glucose < 110 mg/dl, blood pressure < 160/80 mm Hg, normal renal function, (serum creatinine < 1.3 mg/dl (<115 mol/l) and creatinine clearance > 80 ml/min and 1.73 m²), and absence of abnormal proteinuria measured by the Albustix test. Patients with a history of hypertension, diabetes mellitus, renal disease or congestive heart failure were excluded. A group of age and sex matched controls were recruited from healthy hospital workers.

All the patients had a medical history taken and complete physical examination at the first visit. Thereafter patients were evaluated after six, 12, and 18 months. At each visit, a clinical
Urinary albumin excretion in patients with SLE without renal disease

387

expressed as the average of the values obtained from the three urine samples collected for this particular visit. The study was carried out on outpatients.

STATISTICS

A descriptive analysis was done for all the variables. The data are expressed as mean with standard deviation (SD) for the variables normally distributed, or medians with interquartile range for the variables not normally distributed. A two tailed unpaired Student’s t test or Mann-Whitney U test was used to test differences between SLE patients and controls. The Friedman two way analysis of variance was used for repeated measures analysis. p Values greater than 0.05 were considered non-significant. To assess the variability of the UAE in the three daily samples that compose each measurement, the coefficient of variation between them, taken in pairs, was calculated.

Results

Twenty two women of a total of 63 SLE patients were included in the study. They had a mean (SD) age of 39.1 (12.5) years (range: 23–68) and disease duration (SD) of 7.8 (5.0) years (range: 1–21). The control group included 19 women with a mean (SD) age of 42.1 (13.3) years (range: 22–73) (p = NS). Table 1 shows the clinical findings, laboratory data, and treatment received during the study. Twelve patients (12 of 22; 55%) had had anti-dsDNA antibodies before starting the study. There were no significant differences in the creatinine clearance, mean (SD) (range) between the control group 22.8 (28.1) ml/min (84–187) and the SLE patients, at baseline, six, 12, and 18 months of follow up, 130.6 (55.4) (80–290) (p = 0.57), 127.6 (44.3) (81–264) (p = 0.68), 130.7 (53.3) (81–287) (p = 0.59), 121.4 (26.2) (86–173) (p = 0.88), respectively. On the other hand, creatinine clearance in the SLE patients did not show significant changes throughout the study period (Friedman two way analysis of variance, p = 0.74).

Table 1 Clinical features, serological findings, and treatment of 22 SLE patients, without clinical renal disease, during the study period

<table>
<thead>
<tr>
<th>Clinical</th>
<th>Basal (n=22) n, (%)</th>
<th>6 month (n=22) n, (%)</th>
<th>12 month (n=16)* n, (%)</th>
<th>18 month (n=20) n, (%)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Arthritis</td>
<td>9 (41)</td>
<td>5 (23)</td>
<td>3 (19)</td>
<td>1 (5)</td>
</tr>
<tr>
<td>Malar rash</td>
<td>1 (4.5)</td>
<td>1 (4.5)</td>
<td>1 (4.5)</td>
<td>1 (4.5)</td>
</tr>
<tr>
<td>Raynaud</td>
<td>9 (41)</td>
<td>6 (27)</td>
<td>4 (25)</td>
<td>3 (15)</td>
</tr>
<tr>
<td>Pleuritis</td>
<td>1 (4.5)</td>
<td>1 (4.5)</td>
<td>1 (4.5)</td>
<td>1 (4.5)</td>
</tr>
<tr>
<td>Pericarditis</td>
<td>1 (4.5)</td>
<td>0 (0)</td>
<td>0 (0)</td>
<td>0 (0)</td>
</tr>
<tr>
<td>Serological</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Lymphopenia†</td>
<td>7 (32)</td>
<td>2 (9.1)</td>
<td>6 (38)</td>
<td>8 (40)</td>
</tr>
<tr>
<td>ANA</td>
<td>21 (95)</td>
<td>16 (100)</td>
<td>17 (85)</td>
<td></td>
</tr>
<tr>
<td>Anti-dsDNA</td>
<td>5 (23)</td>
<td>4 (25)</td>
<td>3 (15)</td>
<td></td>
</tr>
<tr>
<td>C3‡</td>
<td>9 (41)</td>
<td>9 (41)</td>
<td>6 (38)</td>
<td>6 (30)</td>
</tr>
<tr>
<td>C4‡</td>
<td>8 (36)</td>
<td>10 (45)</td>
<td>4 (25)</td>
<td>7 (35)</td>
</tr>
<tr>
<td>Treatment</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>NSAID</td>
<td>9 (41)</td>
<td>8 (36)</td>
<td>7 (44)</td>
<td>6 (30)</td>
</tr>
<tr>
<td>Prednisone</td>
<td>12 (55)</td>
<td>12 (55)</td>
<td>7 (44)</td>
<td>9 (45)</td>
</tr>
<tr>
<td>Antiimalarial agents</td>
<td>15 (69)</td>
<td>9 (56)</td>
<td>12 (60)</td>
<td></td>
</tr>
<tr>
<td>Methotrexate</td>
<td>0 (0)</td>
<td>1 (4.5)</td>
<td>1 (6)</td>
<td>0 (0)</td>
</tr>
<tr>
<td>Azathioprine</td>
<td>0 (0)</td>
<td>0 (0)</td>
<td>0 (0)</td>
<td>1 (5)</td>
</tr>
<tr>
<td>Cyclophosphamide</td>
<td>0 (0)</td>
<td>0 (0)</td>
<td>0 (0)</td>
<td>1 (5)</td>
</tr>
</tbody>
</table>

* One patient with nephrotic syndrome caused by lupus nephritis is not included at this point time.
† Lymphopenia < 1500/mm³; ‡ C3 < 83 mg/dl; § C4 < 15 mg/dl.
The UAE, median (interquartile range), in the control group was 5.16 (3.33–7.67) μg/min. The UAE, median (interquartile range), in the SLE patients at baseline, six, 12, and 18 months were 5.40 (3.87–7.60) μg/min (p = 0.51), 6.20 (4.73–7.96) μg/min (p = 0.29), 9.38 (4.83–13.46) μg/min (p = 0.03), and 8.86 (4.67–13.72) μg/min (p = 0.03), respectively. Although there were no differences (p > 0.05) in the UAE between the SLE patients and the control group at baseline and six months of follow up, we found some increased UAE rates in SLE patients at 12 and 18 months (p < 0.05) when compared with healthy controls. Consistent with these findings, we also found a significant intragroup difference in the UAE rate of SLE patients throughout the study period (Friedman two way analysis of variance, p = 0.01). As expected by the data mentioned above, the coefficients of variation for the UAE, calculated from the three overnight urine samples at each follow up visit, were larger in the SLE patients (mean 65%, range: 26–141%) than in the healthy controls (mean 41%, range: 28–54%). We failed to find any relation between disease activity and UAE.

Only five SLE patients had UAE values above 20 μg/min at some point during the study. Four of these patients had microalbuminuria (20–200 μg/min) only at some visits, but all were transient and of low magnitude, ranging from 20 to 41 μg/min, and no urine sample exceeded the upper limit of the range defined as microalbuminuria (> 200 μg/min). Two of these four patients were taking a non-steroidal anti-inflammatory drug (NSAID) when microalbuminuria appeared. None of these four patients had hypertension or any data suggestive of clinical nephropathy during an additional three years of follow up after the end of the study. The fifth patient, whose UAE at baseline (4.67 μg/min) and six month (4.73 μg/min) visits were normal, presented with a nephrotic syndrome at 12 months after starting the study, and her kidney biopsy showed diffuse proliferative lupus glomerulonephritis. She was treated with prednisone and monthly doses of intravenous cyclophosphamide with complete disappearance of proteinuria (Albustix negative). Six months after the start of this treatment her UAE had returned to normal values (4.65 μg/min), her renal function was normal, and she was normotensive.

It seems that some patients with lupus and without clinical renal disease have wider oscillations in UAE than healthy people, although this does not seem to warrant any specific action. It is of special interest that in one of the patients, the first two UAE measurements failed to predict the development of severe renal disease. Furthermore, after treatment, her UAE returned to normal baseline values, below the level of microalbuminuria. These data are in contrast with the high predictive value of the appearance of urinary cellular casts for renal relapse in SLE patients with confirmed renal disease.23 Our findings cannot exclude that a more frequent measurement of UAE, for example at two monthly intervals, could show a rising value before proteinuria becomes obvious. The rate at which proteinuria develops in patients whose
glomeruli are becoming inflamed is not well known, but probably in those patients who suffer from an acute inflammatory process it develops over a short period of time and cannot be predicted through UAE. Whether UAE may help to evaluate the residual glomerular damage after successful treatment of lupus glomerulonephritis merits some consideration.

Urinary albumin excretion in patients with systemic lupus erythematosus without renal disease

Enrique Batlle-Gualda, Ana Carro Martínez, Rocío Alfayate Guerra and Eliseo Pascual

Ann Rheum Dis 1997 56: 386-389
doi: 10.1136/ard.56.6.386

Updated information and services can be found at:
http://ard.bmj.com/content/56/6/386

These include:

References
This article cites 22 articles, 5 of which you can access for free at:
http://ard.bmj.com/content/56/6/386#BIBL

Email alerting service
Receive free email alerts when new articles cite this article. Sign up in the box at the top right corner of the online article.

Topic Collections
Articles on similar topics can be found in the following collections
- Pathology (444)
- Connective tissue disease (4253)
- Immunology (including allergy) (5144)
- Systemic lupus erythematosus (571)
- Clinical diagnostic tests (1282)
- Drugs: musculoskeletal and joint diseases (700)
- Radiology (1113)
- Renal medicine (204)
- Surgical diagnostic tests (431)

Notes

To request permissions go to:
http://group.bmj.com/group/rights-licensing/permissions

To order reprints go to:
http://journals.bmj.com/cgi/reprintform

To subscribe to BMJ go to:
http://group.bmj.com/subscribe/